In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?

John Carroll

Editor & Founder

After spending the past 8 years scripting a turnaround that would make AstraZeneca $AZN a reliable growth story and global performer in oncology, CEO Pascal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

In an end-of-year sur­prise, As­traZeneca nabs rare dis­ease stal­wart Alex­ion in $39B buy­out. But why?

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?